Table 2.
Pyogenic Liver Abscess Characteristics and Management
| Characteristics | All Patients (n = 124) | Nonmalignancy Subgroup (n = 64) | Malignancy Subgroup (n = 60) | P Values |
|---|---|---|---|---|
| Abscess size (cm), no. (%) | .1263 | |||
| <5 cm | 35 (28) | 13 (20) | 22 (37) | |
| >5 cm | 54 (44) | 29 (45) | 25 (42) | |
| Unknown | 35 (28) | 22 (34) | 13 (22) | |
| Abscess number, no. (%) | .3778 | |||
| Single | 82 (66) | 40 (63) | 42 (70) | |
| Multiple | 42 (34) | 24 (37) | 18 (30) | |
| Microbiology, no. (%) | ||||
| VRE | 1 (1) | 0 (0) | 1 (2) | .4839 |
| ESBL producers | 2 (2) | 1 (2) | 1 (2) | 1 |
| Escherichia coli | 9 (7) | 5 (8) | 4 (7) | .8246 |
| Klebsiella pneumoniae | 2 (2) | 1 (2) | 1 (2) | 1 |
| Streptococcus anginosus group | 11 (9) | 7 (11) | 4 (7) | .4186 |
| All other Gram positives | 6 (5) | 5 (8) | 1 (2) | .1154 |
| All other Gram negatives | 11 (9) | 5 (8) | 6 (10) | .6491 |
| Anaerobes | 17 (14) | 12 (19) | 5 (8) | .0919 |
| Polymicrobial | 40 (32) | 18 (28) | 22 (37) | .3092 |
| Fungal | 3 (2) | 0 (0) | 3 (5) | .1103 |
| Unknown | 22 (18) | 10 (16) | 12 (20) | .5239 |
| Inpatient intervention, no. (%) | ||||
| Surgery | 12 (10) | 7 (11) | 5 (8) | .6240 |
| Percutaneous aspiration | 23 (19) | 12 (19) | 11 (18) | .9524 |
| Percutaneous drainage | 78 (63) | 39 (61) | 39 (65) | .6398 |
| Antibiotics alone | 11 (9) | 6 (9) | 5 (8) | .8384 |
| Biliary drainage, no. (%) | ||||
| Cholecystectomy | 8 (6) | 7 (11) | 1 (1) | .0357 |
| Percutaneous drainage | 6 (5) | 2 (3) | 4 (7) | .3584 |
| Biliary stenting | 15 (12) | 5 (8) | 10 (17) | .1308 |
| None | 95 (77) | 50 (78) | 45 (75) | .6812 |
| ID consult on initial admission, no. (%) | 78 (63) | 42 (66) | 36 (60) | .5170 |
| Length of stay, mean (range) | 11 (2–108) | 13.5 (2–108) | 9.3 (2–38) | .072 |
| Mortality from PLA in-hospital, no. (%) | 5 (4) | 4 (6) | 1 (2) | .2009 |
Abbreviations: ESBL, extended-spectrum β-lactamase; ID, infectious diseases; PLA, pyogenic liver abscesses; VRE, vancomycin-resistant Enterococcus.